Cyramza plus Tagrisso significantly extended PFS in TKI-naïve EGFR-mutant NSCLC patients compared to Tagrisso alone, with a median PFS of 24.8 vs. 15.6 months. PFS benefits were consistent across ...
Tagrisso has been approved for some adults with locally advanced, unresectable stage 3 non-small cell lung cancer. The Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for adults ...
Tagrisso, with chemotherapy, reduced the risk of disease progression or death by 38% by investigator assessment vs. Tagrisso monotherapy. Median progression-free survival was 25.5 months in Tagrisso ...
Around 30,000 people annually in the U.S. with non-small cell lung cancer (NSCLC) also get diagnosed with specific epidermal growth factor receptor (EGFR) gene mutations, a condition that affects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback